Loss of GPR133 Promotes Enzalutamide Resistance in Prostate Cancer by Upregulating HSD3B1 and Intratumoral Androgen Synthesis [0.03%]
GPR133丢失通过上调HSD3B1和肿瘤内的雄激素合成促进前列腺癌耐药性的发展
Lai Wei,Ziwei Wang,Dajun Gao et al.
Lai Wei et al.
Background: The progression of prostate cancer (PCa) to a castration-resistant state (CRPC) remains a major clinical challenge. Resistance to second-generation androgen receptor (AR) antagonists like enzalutamide often in...
Correction to "[Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study (The Prostate, 2025). https://doi.org/10.1002/pros.70071]" [0.03%]
对“塞诺宁提取物联合阿夫唑嗪与单用阿夫唑嗪治疗良性前列腺增生所致下尿路症状的疗效：一项多中心随机研究”的校正论文
Published Erratum
The Prostate. 2026 Feb 9. DOI:10.1002/pros.70141 2026
Toward a Modern Telehealth Follow-Up Routine for Radical Prostatectomy: Introducing a Novel E-Health Application for Outcome and Complication Assessment [0.03%]
前列腺癌根治术后现代远程医疗随访体系的建立及新型移动医疗应用软件的发展与评估
Nora Bauer,Christian Daniel Fankhauser,Silvan Sigg et al.
Nora Bauer et al.
Background: To implement "MeinLUKS," an automated e-health follow-up system within the EPIC MyChart portal after radical prostatectomy (RP), and to examine factors influencing portal adoption, as well as functional and on...
Happening in the Prostate Tumor Microenvironment: Ion Channels and Extrachromosomal DNA Driving Phenotypic Plasticity [0.03%]
前列腺肿瘤微环境中的离子通道和细胞质DNA驱动的表型可塑性事件
Sara Darbandi,Alfonso Urbanucci,Sini Hakkola et al.
Sara Darbandi et al.
Background: Plasticity of cancer, including epithelial-mesenchymal transition (EMT), cancer stem cell (CSC) self-renewal, and microenvironmental adaptation, drives metastasis, therapy resistance, and poor outcomes in pros...
Review
The Prostate. 2026 Feb 3. DOI:10.1002/pros.70139 2026
Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809) [0.03%]
卡那奴单抗联合MK-2206治疗初始治疗后PSA升高的前列腺癌患者的II期随机研究（ECOG-ACRIN E2809）
Anna C Ferrari,Yu-Hui Chen,Ronald Rodríguez et al.
Anna C Ferrari et al.
Background: Combined inhibition of AKT and the androgen receptor (AR) might be more efficacious than AR inhibition alone in biochemical recurrence (BCR) of prostate cancer (PC) by additive effects on the two effector path...
The Sign of Leser-Trélat as a Possible Indicator of Prostate Adenocarcinoma: A Case Report [0.03%]
Leser-Trelat征提示前列腺腺癌1例报告
Hristo Dobrev
Hristo Dobrev
Backgrounds: The sign of Leser-Trélat (SLT) is defined by the abrupt onset of multiple pruritic or nonpruritic seborrhoeic keratoses (SKs) over a short interval, predominantly affecting the back, and is most frequently a...
External Validation of the Martini-Klinik Nomogram Predicting the Indication for Adjuvant Radiation Therapy According to EAU Guidelines Among Patients With High-Risk Prostate Cancer After Radical Prostatectomy [0.03%]
马蒂尼诊所列线图预测高危前列腺癌根治术后放射治疗的外部验证
Carolin Siech,Tonio Brüggemann,Quynh Chi Le et al.
Carolin Siech et al.
Objective: To externally validate the Martini-Klinik nomogram based on patient and clinical tumor characteristics predicting the indication for adjuvant radiation therapy after radical prostatectomy according to guideline...
Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis [0.03%]
吸烟对前列腺癌治疗结果的基因组学和临床影响：公共数据库分析
Tomoya Hatayama,Yohei Sekino,Go Kobayashi et al.
Tomoya Hatayama et al.
Background: In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impac...
Evaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer [0.03%]
评估Y染色体丢失作为外周血前列腺癌生物标志物的价值
Jun Lu,Yan Lu,Takuro Kobayashi et al.
Jun Lu et al.
Background: Prostate cancer (PCa) is the most common malignant tumor in men, but the widely used prostate-specific antigen (PSA) test has limited diagnostic accuracy. Research proposes that the loss of the Y chromosome (L...
Effect of Celecoxib Combined With Low-Dose-Rate Brachytherapy on Long-Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open-Label Controlled Randomized Trial [0.03%]
一项开放标签对照随机试验的事后分析：塞来昔布联合低剂量率组织间植入治疗对前列腺癌患者的长期肿瘤学疗效和生活质量的影响
Yasushi Nakai,Kenta Onishi,Isao Asakawa et al.
Yasushi Nakai et al.
Background: Long-term clinical data evaluating oncological outcomes and patient-reported quality of life (QOL) after combining celecoxib with radiotherapy are lacking. Therefore, we aimed to assess oncological outcomes an...